Publications:

---

PGLYRP1-mIgG2a-Fc inhibits macrophage activation via AKT/NF-κB signaling and protects against fatal lung injury during bacterial infection.

Iscience

Jia, Yan Y; Ren, Shan S; Song, Luyao L; Wang, Siyi S; Han, Wei W; Li, Jingjing J; Yu, Yan Y; Ma, BuYong B

Publication Date: 2023-05-19

Variant appearance in text: PI3K: L234A

PubMed Link: 37113764

Variant Present in the following documents:

• main.pdf

View BVdb publication page

---

An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.

Nature Cancer

Chan, Sarah S; Belmar, Nicole N; Ho, Sun S; Rogers, Bryan B; Stickler, Marcia M; Graham, Michelle M; Lee, Eileen E; Tran, Ninian N; Zhang, Dong D; Gupta, Priyanka P; Sho, Mien M; MacDonough, Tracy T; Woolley, Andrew A; Kim, Han H; Zhang, Hong H; Liu, Wei W; Zheng, Pingping P; Dezso, Zoltan Z; Halliwill, Kyle K; Ceccarelli, Michele M; Rhodes, Susan S; Thakur, Archana A; Forsyth, Charles M CM; Xiong, Mengli M; Tan, Siu Sze SS; Iyer, Ramesh R; Lake, Marc M; Digiammarino, Enrico E; Zhou, Li L; Bigelow, Lance L; Longenecker, Kenton K; Judge, Russell A RA; Liu, Cassie C; Trumble, Max M; Remis, Jonathan P JP; Fox, Melvin M; Cairns, Belinda B; Akamatsu, Yoshiko Y; Hollenbaugh, Diane D; Harding, Fiona F; Alvarez, Hamsell M HM

Publication Date: 2022-03

Variant appearance in text: PI3K: L234A

PubMed Link: 35256819

Variant Present in the following documents:

• Main text
• 43018_2022_Article_334.pdf

View BVdb publication page

---

Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer.

Biomolecules & Therapeutics

Lee, Ji Eun JE; Woo, Min Gyu MG; Jung, Kyung Hee KH; Kang, Yeo Wool YW; Shin, Seung-Min SM; Son, Mi Kwon MK; Fang, Zhenghuan Z; Yan, Hong Hua HH; Park, Jung Hee JH; Yoon, Young-Chan YC; Kim, Yong-Sung YS; Hong, Soon-Sun SS

Publication Date: 2022-05-01

Variant appearance in text: PI3K: L234A

PubMed Link: 34663758

Variant Present in the following documents:

• Main text
• bt-30-3-274.pdf

View BVdb publication page

---

Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment.

Antibodies (Basel, Switzerland)

Liu, Rena R; Oldham, Robert J RJ; Teal, Emma E; Beers, Stephen A SA; Cragg, Mark S MS

Publication Date: 2020-11-17

Variant appearance in text: PI3K: L234A

PubMed Link: 33212886

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.

Science Advances

Shin, Seung-Min SM; Kim, Ji-Sun JS; Park, Seong-Wook SW; Jun, Sei-Yong SY; Kweon, Hye-Jin HJ; Choi, Dong-Ki DK; Lee, Dakeun D; Cho, Yong Beom YB; Kim, Yong-Sung YS

Publication Date: 2020-01

Variant appearance in text: PI3K: L234A

PubMed Link: 31998840

Variant Present in the following documents:

• Main text
• aay2174.pdf

View BVdb publication page

---

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.

Oncoimmunology

Pazina, Tatiana T; James, Ashley M AM; MacFarlane, Alexander W AW; Bezman, Natalie A NA; Henning, Karla A KA; Bee, Christine C; Graziano, Robert F RF; Robbins, Michael D MD; Cohen, Adam D AD; Campbell, Kerry S KS

Publication Date: 2017

Variant appearance in text: PI3K: L234A

PubMed Link: 28932638

Variant Present in the following documents:

• Main text

View BVdb publication page

---